@article {Zhou:2020:2158-5849:350,
title = "Evaluation of a recombinant bacillus calmette-gu{\’e}rin vaccine expressing P39-L7/L12 of Brucella melitensis: An immunization strategy against brucellosis in BALB/c mice",
journal = "Materials Express",
parent_itemid = "infobike://asp/me",
publishercode ="asp",
year = "2020",
volume = "10",
number = "3",
publication date ="2020-03-01T00:00:00",
pages = "350-362",
itemtype = "ARTICLE",
issn = "2158-5849",
url = "https://www.ingentaconnect.com/content/asp/me/2020/00000010/00000003/art00005",
doi = "doi:10.1166/mex.2020.1645",
keyword = "Vaccine, Recombinant BCG, Brucellosis, P39-L7/12",
author = "Zhou, Yumei and Zheng, Yuanqiang and Chen, Yajing and Li, Yajing and Sun, Xiaoying and Huo, Yujuan and Shi, Yanchun",
abstract = "Brucellosis is a chronic infectious disease caused by bacteria from the genus Brucella. It has a serious global economic impact, and poses a threat to public health. Ideally, vaccines should exhibit a safe profile as well as enhanced protective efficacy. However, there are no licensed
vaccines available for humans against brucellosis. In this study, for the first time, a recombinant BCG (rBCG) vaccine expressing the P39-L7/12 fusion protein of Brucella melitensis against brucellosis was constructed. The rBCG vaccine elicited strong antigen-specific humoral and T cell-mediated
immunity in vivo. The rBCG vaccine also induced a significant level of protection following challenge with a virulent strain of B. melitensis M28 in BALB/c mice. Furthermore, the protection level induced by the rBCG vaccine was significantly higher than that induced by BCG. Collectively, these
results suggested that rBCG vaccine acted as a suitable vaccine candidate and a new strategy against human brucellosis.",
}